Prevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate

Daire O'Shea, John Law, Adrian Egli, Donna Douglas, Gary Lund, Sarah Forester, Joshua Lambert, Mansun Law, Dennis R. Burton, D. L.J. Tyrrell, Michael Houghton, Atul Humar, Norman Kneteman

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

The anti-hepatitis C virus (HCV) activity of a novel monoclonal antibody (mAb; AR4A) and epigallocatechin gallate (EGCG) were studied in vitro using a HCV cell culture system and in vivo using a humanized liver mouse model capable of supporting HCV replication. Alone, both exhibit reliable cross-genotype HCV inhibition in vitro, and combination therapy completely prevented HCV infection. In vitro AR4A mAb (alone and combined with EGCG) robustly protects against the establishment of HCV genotype 1a infection. EGCG alone fails to reliably protect against an HCV challenge. In conclusion, AR4A mAb represents a safe and efficacious broadly neutralizing antibody against HCV applicable to strategies to safely prevent HCV reinfection following liver transplantation, and it lends further support to the concept of HCV vaccine development. The poor bioavailability of EGCG limits HCV antiviral activity in vitro. Liver Transpl 22:324-332, 2016.

Original languageEnglish (US)
Pages (from-to)324-332
Number of pages9
JournalLiver Transplantation
Volume22
Issue number3
DOIs
StatePublished - Mar 1 2016

All Science Journal Classification (ASJC) codes

  • Surgery
  • Hepatology
  • Transplantation

Fingerprint Dive into the research topics of 'Prevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate'. Together they form a unique fingerprint.

  • Cite this

    O'Shea, D., Law, J., Egli, A., Douglas, D., Lund, G., Forester, S., Lambert, J., Law, M., Burton, D. R., Tyrrell, D. L. J., Houghton, M., Humar, A., & Kneteman, N. (2016). Prevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate. Liver Transplantation, 22(3), 324-332. https://doi.org/10.1002/lt.24344